The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of Catalent (CTLT) by Novo Holdings. The Commission concluded that the transaction would not raise competition concerns in the European Economic Area. Novo Holdings is the ultimate owner of Novo Nordisk (NVO). The Commission concluded that the proposed merger would not raise competition concerns on any of the markets examined in the EEA or on any substantial part of it. It therefore cleared the transaction unconditionally.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CTLT:
- Novo slated to win EU approval for Catalent takeover, Reuters says
- Catalent Inc. Reports Q1 Fiscal 2025 Results
- Catalent reports Q1 EPS (13c), consensus 5c
- CTLT Earnings this Week: How Will it Perform?
- Catalent issues letter to customers regarding acquisition by Novo Holdings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
